A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.
El Zawily A, Vizeacoumar FS, Dahiya R, Banerjee SL, Bhanumathy KK, Elhasasna H, Hanover G, Sharpe JC, Sanchez MG, Greidanus P, Stacey RG, Moon KM, Alexandrov I, Himanen JP, Nikolov DB, Fonge H, White AP, Foster LJ, Wang B, Toosi BM, Bisson N, Mirzabekov TA, Vizeacoumar FJ, Freywald A.
El Zawily A, et al. Among authors: freywald a.
Clin Cancer Res. 2023 Jul 14;29(14):2686-2701. doi: 10.1158/1078-0432.CCR-22-2535.
Clin Cancer Res. 2023.
PMID: 36976175
Free PMC article.